Your browser doesn't support javascript.
loading
Management of Lung Cancer Screening Results Based on Individual Prediction of Current and Future Lung Cancer Risks.
Robbins, Hilary A; Cheung, Li C; Chaturvedi, Anil K; Baldwin, David R; Berg, Christine D; Katki, Hormuzd A.
Afiliação
  • Robbins HA; International Agency for Research on Cancer, Lyon, France. Electronic address: RobbinsH@iarc.fr.
  • Cheung LC; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
  • Chaturvedi AK; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
  • Baldwin DR; University of Nottingham, Nottingham, United Kingdom.
  • Berg CD; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
  • Katki HA; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
J Thorac Oncol ; 17(2): 252-263, 2022 02.
Article em En | MEDLINE | ID: mdl-34648946
ABSTRACT

OBJECTIVES:

We propose a risk-tailored approach for management of lung cancer screening results. This approach incorporates individual risk factors and low-dose computed tomography (LDCT) image features into calculations of immediate and next-screen (1-y) risks of lung cancer detection, which in turn can recommend short-interval imaging or 1-year or 2-year screening intervals.

METHODS:

We first extended the "LCRAT+CT" individualized risk calculator to predict lung cancer risk after either a negative or abnormal LDCT screen result. To develop the abnormal screen portion, we analyzed 18,129 abnormal LDCT results in the National Lung Screening Trial (NLST), including lung cancers detected immediately (n = 649) or at the next screen (n = 235). We estimated the potential impact of this approach among NLST participants with any screen result (negative or abnormal).

RESULTS:

Applying the draft National Health Service (NHS) England protocol for lung screening to NLST participants referred 76% of participants to a 2-year interval, but delayed diagnosis for 40% of detectable cancers. The Lung Cancer Risk Assessment Tool+Computed Tomography (LCRAT+CT) risk model, with a threshold of less than 0.95% cumulative lung cancer risk, would also refer 76% of participants to a 2-year interval, but would delay diagnosis for only 30% of cancers, a 25% reduction versus the NHS protocol. Alternatively, LCRAT+CT, with a threshold of less than 1.7% cumulative lung cancer risk, would also delay diagnosis for 40% of cancers, but would refer 85% of participants for a 2-year interval, a 38% further reduction in the number of required 1-year screens beyond the NHS protocol.

CONCLUSIONS:

Using individualized risk models to determine management in lung cancer screening could substantially reduce the number of screens or increase early detection.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Detecção Precoce de Câncer / Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: En Revista: J Thorac Oncol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Detecção Precoce de Câncer / Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: En Revista: J Thorac Oncol Ano de publicação: 2022 Tipo de documento: Article